279 related articles for article (PubMed ID: 27129260)
1. EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.
Wilson M; Tsakraklides V; Tran M; Xiao YY; Zhang Y; Perkins AS
J Biol Chem; 2016 Jun; 291(26):13591-607. PubMed ID: 27129260
[TBL] [Abstract][Full Text] [Related]
2. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
[TBL] [Abstract][Full Text] [Related]
3. RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.
Tokita K; Maki K; Mitani K
Cancer Sci; 2007 Nov; 98(11):1752-7. PubMed ID: 17894555
[TBL] [Abstract][Full Text] [Related]
4. The role of EVI1 in normal and leukemic cells.
Buonamici S; Chakraborty S; Senyuk V; Nucifora G
Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
[TBL] [Abstract][Full Text] [Related]
5. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
[TBL] [Abstract][Full Text] [Related]
6. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Deletion of the Cebpa +37 kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis.
Guo H; Cooper S; Friedman AD
PLoS One; 2016; 11(3):e0150809. PubMed ID: 26937964
[TBL] [Abstract][Full Text] [Related]
8. Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.
Maki K; Sugita F; Nakamura Y; Sasaki K; Mitani K
Int J Hematol; 2013 Jan; 97(1):83-91. PubMed ID: 23250858
[TBL] [Abstract][Full Text] [Related]
9. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
[TBL] [Abstract][Full Text] [Related]
10. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
[TBL] [Abstract][Full Text] [Related]
11. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
Cooper S; Guo H; Friedman AD
PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
[TBL] [Abstract][Full Text] [Related]
12. HoxA9 binds and represses the Cebpa +8 kb enhancer.
Peng L; Guo H; Ma P; Sun Y; Dennison L; Aplan PD; Hess JL; Friedman AD
PLoS One; 2019; 14(5):e0217604. PubMed ID: 31120998
[TBL] [Abstract][Full Text] [Related]
13. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
14. EVI1 abrogates interferon-alpha response by selectively blocking PML induction.
Buonamici S; Li D; Mikhail FM; Sassano A; Platanias LC; Colamonici O; Anastasi J; Nucifora G
J Biol Chem; 2005 Jan; 280(1):428-36. PubMed ID: 15519999
[TBL] [Abstract][Full Text] [Related]
15. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
[TBL] [Abstract][Full Text] [Related]
16. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
[TBL] [Abstract][Full Text] [Related]
17. Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR.
Boyd KE; Xiao YY; Fan K; Poholek A; Copeland NG; Jenkins NA; Perkins AS
Blood; 2006 Jan; 107(2):733-41. PubMed ID: 16204320
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.
Nishikawa S; Arai S; Masamoto Y; Kagoya Y; Toya T; Watanabe-Okochi N; Kurokawa M
Blood; 2014 Dec; 124(24):3587-96. PubMed ID: 25298035
[TBL] [Abstract][Full Text] [Related]
19. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
20. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
Sitailo S; Sood R; Barton K; Nucifora G
Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
